Familial hypercholesterolaemia
KEYWORDS: people, diagnosis, quality, statement, data, treatment, testing, clinical, children, specialist, hypercholesterolaemia, familial hypercholesterolaemia, clinical diagnosis, familial, source

need to stop statins for several years when they are trying to conceive, and during pregnancy and breastfeeding. Because the accumulation of LDL-C burden is similar in boys and girls, this will result in the exposure to high LDL-C being greater in early adulthood in young women than in their male siblings. Gender should not influence a clinician's decision to offer treatment; the decision should be made in accordance with the recommendations in NICE's guideline on familial hypercholesterolaemia, which indicate that lipid lowering with statins should be considered by the age of 10 years. Quality statement 8: Annual review Quality statement People with familial hypercholesterolaemia (FH) are offered a structured review at least annually. Rationale Regular structured review enables treatment to be monitored and adjusted to achieve the recommended LDL-C concentration. It also enables monitoring for the possible development of symptoms and signs of coronary heart disease and optimising management. Records can be maintained of affected family members and information can be tailored to individual circumstances. Progress with cascade testing of at-risk relatives can be monitored. Quality measures The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples
